

Board Changes Effected

Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: **RHY**) (“**Rhythm**” or the “**Company**”) is pleased to confirm the appointment of Mr Gavin Fox-Smith to the Board of the Company today, as previously advised on 11 November 2024. Also as advised on 20 November 2024, effective today, Ms Sue MacLeman has stepped back to the position of Non-Executive Director.

The Board comprises a majority of Non-Executive Directors, with Dr David Atkins the Company’s Managing Director and Chief Executive Officer holding the only executive position on the Board.

Rhythm Non-Executive Chairman, Otto Buttula, commented:

“On behalf of the Company, I would like to thank Sue for capably carrying out the role of Independent Non-Executive Deputy Chair over the last 17 months. We are also pleased to formally welcome Gavin to the Board. Gavin has a wealth of appropriate experience to be able to contribute to Rhythm’s future endeavours. As well as being a Board Member of Bowel Cancer Australia, Gavin has expressed a particular drive to enhancing public health, in particular in the early detection of bowel cancer in order to improve patient outcomes.”

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investors@rhythmbio.com:

David Atkins, PhD Managing Director / Chief Executive Officer	Andrea Steele General Counsel & Joint Company Secretary
---	---

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT® Test-Kit is Rhythm Bioscience’s simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. It is being updated to meet relevant regulatory standards.

The ColoSTAT® Test-Kit is based on research from Australia’s CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

Directors